PGT-A
Preimplantation genetic testing for aneuploidy (PGT-A) boosts chances of your fertility success by giving us valuable genetic insights.
PGT-A's Vital Role in IVF Treatments
PGT-A empowers our expert fertility specialists to assess embryos for chromosomal abnormalities before implantation, significantly improving the chances of a successful pregnancy and healthy birth. By identifying the most viable embryos with the correct number of chromosomes, we can tailor IVF treatments to individual patients, ensuring the highest likelihood of a successful pregnancy.
At IVF1, we are proud to offer PGT-A as part of our comprehensive fertility solutions, providing hope and exceptional care as you embark on your journey towards parenthood.
PGT-A FAQ
PGT-A, or preimplantation genetic testing for aneuploidy, is a specialized procedure used in conjunction with IVF. It tests embryos for chromosomal abnormalities before they are implanted in the uterus. A small biopsy from each embryo is taken and its chromosomes are analyzed to check for the correct number of chromosomes (euploidy) or an abnormal number (aneuploidy). Aneuploidy can lead to implantation failure, miscarriages, or genetic disorders like Down Syndrome.
PGT-A is often recommended for couples with a history of recurrent miscarriages, unsuccessful IVF cycles, advanced maternal age, or known chromosomal disorders. It is also considered by those who want to increase their chances of a successful pregnancy and decrease the likelihood of chromosomal abnormalities.
The primary benefit of PGT-A is the increased likelihood of a successful pregnancy and a healthy baby. It reduces the risk of miscarriage and the birth of a child with a chromosomal disorder. It can also help select the best embryo for transfer, potentially reducing the number of IVF cycles needed.
The risks associated with PGT-A are generally low but include potential damage to the embryo during biopsy. There's also a slight chance of false positives or negatives. It's important to note that PGT-A does not test for single gene disorders or guarantee a successful pregnancy; it only screens for chromosomal normalcy.
PGT-A adds an extra step to the IVF process. After egg retrieval and fertilization, embryos are grown in the lab for about five to six days. Then, a few cells are biopsied and sent for genetic analysis. While awaiting results, embryos are usually frozen. Once the analysis is complete, a genetically normal embryo is selected for transfer in a subsequent IVF cycle. This process can extend the time frame of IVF but can improve the chances of a successful, healthy pregnancy.
